Generex Biotechnology Corporation (GNBT) Announces New Treatment IND Site for the US FDA Expanded Access Treatment IND Program for Generex Oral-lyn(tm) in the United States
4/13/2010 9:11:21 AM
WORCESTER, Mass., April 13, 2010 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (Nasdaq:GNBT) (www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that John Muir Physician Network Clinical Research Center has agreed to participate in the United States Food and Drug Administration (FDA) Expanded Access Treatment Investigational New Drug (IND) Program for the Company's flagship product, Generex Oral-lyn™, a proprietary buccal insulin spray product. In September 2009, the FDA approved the treatment use of Generex Oral-lyn™ under the FDA's Treatment IND Program.
comments powered by